251 related articles for article (PubMed ID: 24033843)
1. Outcomes of combination therapy for chronic antibody-mediated rejection in renal transplantation.
Kim MG; Kim YJ; Kwon HY; Park HC; Koo TY; Jeong JC; Jeon HJ; Han M; Ahn C; Yang J
Nephrology (Carlton); 2013 Dec; 18(12):820-6. PubMed ID: 24033843
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness of rituximab and intravenous immunoglobulin therapy in renal transplant recipients with chronic active antibody-mediated rejection.
Hong YA; Kim HG; Choi SR; Sun IO; Park HS; Chung BH; Choi BS; Park CW; Kim YS; Yang CW
Transplant Proc; 2012 Jan; 44(1):182-4. PubMed ID: 22310610
[TBL] [Abstract][Full Text] [Related]
3. Treatment of Biopsy-Proven Acute Antibody-Mediated Rejection Using Thymoglobulin (ATG) Monotherapy and a Combination of Rituximab, Intravenous Immunoglobulin, and Plasmapheresis: Lesson Learned from Primary Experience.
Zheng J; Xue W; Qing X; Jing X; Hou J; Tian X; Guo Q; He X; Cai J
Clin Transpl; 2014; ():223-30. PubMed ID: 26281149
[TBL] [Abstract][Full Text] [Related]
4. The influence of bortezomib on donor specific antibody reduction in patients with antibody mediated rejection.
Hardinger KL; Murillo D
Clin Transpl; 2011; ():401-8. PubMed ID: 22755438
[TBL] [Abstract][Full Text] [Related]
5. Successful treatment of chronic antibody-mediated rejection with IVIG and rituximab in pediatric renal transplant recipients.
Billing H; Rieger S; Ovens J; Süsal C; Melk A; Waldherr R; Opelz G; Tönshoff B
Transplantation; 2008 Nov; 86(9):1214-21. PubMed ID: 19005402
[TBL] [Abstract][Full Text] [Related]
6. Intensive plasmapheresis and intravenous immunoglobulin for treatment of antibody-mediated rejection after kidney transplant.
Ruangkanchanasetr P; Satirapoj B; Termmathurapoj S; Namkhanisorn K; Suaywan K; Nimkietkajorn V; Luesutthiviboon L
Exp Clin Transplant; 2014 Aug; 12(4):328-33. PubMed ID: 25095710
[TBL] [Abstract][Full Text] [Related]
7. Comparison between bortezomib and rituximab in the treatment of antibody-mediated renal allograft rejection.
Waiser J; Budde K; Schütz M; Liefeldt L; Rudolph B; Schönemann C; Neumayer HH; Lachmann N
Nephrol Dial Transplant; 2012 Mar; 27(3):1246-51. PubMed ID: 21852274
[TBL] [Abstract][Full Text] [Related]
8. Differential modulation of donor-specific antibodies after B-cell depleting therapies to cure chronic antibody mediated rejection.
Touzot M; Couvrat-Desvergnes G; Castagnet S; Cesbron A; Renaudin K; Cantarovich D; Giral M
Transplantation; 2015 Jan; 99(1):63-8. PubMed ID: 25029384
[TBL] [Abstract][Full Text] [Related]
9. Late antibody-mediated rejection in renal allografts: outcome after conventional and novel therapies.
Gupta G; Abu Jawdeh BG; Racusen LC; Bhasin B; Arend LJ; Trollinger B; Kraus E; Rabb H; Zachary AA; Montgomery RA; Alachkar N
Transplantation; 2014 Jun; 97(12):1240-6. PubMed ID: 24937198
[TBL] [Abstract][Full Text] [Related]
10. Clinical outcome in patients with chronic antibody-mediated rejection treated with and without rituximab and intravenous immunoglobulin combination therapy.
Chung BH; Kim Y; Jeong HS; Hong YA; Choi BS; Park CW; Choi YJ; Kim YS; Yang CW
Transpl Immunol; 2014 Sep; 31(3):140-4. PubMed ID: 25179826
[TBL] [Abstract][Full Text] [Related]
11. Frequent development of subclinical chronic antibody-mediated rejection within 1 year after renal transplantation with pre-transplant positive donor-specific antibodies and negative CDC crossmatches.
Yamanaga S; Watarai Y; Yamamoto T; Tsujita M; Hiramitsu T; Nanmoku K; Goto N; Takeda A; Morozumi K; Katayama A; Saji H; Uchida K; Kobayashi T
Hum Immunol; 2013 Sep; 74(9):1111-8. PubMed ID: 23792054
[TBL] [Abstract][Full Text] [Related]
12. Reduction of alloantibodies via proteasome inhibition in cardiac transplantation.
Patel J; Everly M; Chang D; Kittleson M; Reed E; Kobashigawa J
J Heart Lung Transplant; 2011 Dec; 30(12):1320-6. PubMed ID: 21968130
[TBL] [Abstract][Full Text] [Related]
13. Four-year allograft survival in a highly sensitized combined liver-kidney transplant patient despite unsuccessful anti-HLA antibody reduction with rituximab, splenectomy, and bortezomib.
Koch M; Gräser C; Lehnhardt A; Pollok JM; Kröger N; Verboom M; Thaiss F; Eiermann T; Nashan B
Transpl Int; 2013 Aug; 26(8):e64-8. PubMed ID: 23672514
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of bortezomib for reducing donor-specific antibodies in children and adolescents on a steroid minimization regimen.
Nguyen S; Gallay B; Butani L
Pediatr Transplant; 2014 Aug; 18(5):463-8. PubMed ID: 24814755
[TBL] [Abstract][Full Text] [Related]
15. Intravenous immunoglobulins and rituximab therapy for severe transplant glomerulopathy in chronic antibody-mediated rejection: a pilot study.
Bachelet T; Nodimar C; Taupin JL; Lepreux S; Moreau K; Morel D; Guidicelli G; Couzi L; Merville P
Clin Transplant; 2015 May; 29(5):439-46. PubMed ID: 25739833
[TBL] [Abstract][Full Text] [Related]
16. IVIG and rituximab for treatment of chronic antibody-mediated rejection: a prospective study in paediatric renal transplantation with a 2-year follow-up.
Billing H; Rieger S; Süsal C; Waldherr R; Opelz G; Wühl E; Tönshoff B
Transpl Int; 2012 Nov; 25(11):1165-73. PubMed ID: 22897111
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of Bortezomib as an Adjunctive Therapy for Refractory Chronic Active Antibody-Mediated Rejection in Kidney Transplant Patients: A Single-Center Experience.
Larpparisuth N; Skulratanasak P; Premasathian N; Vongwiwatana A
Transplant Proc; 2019 Dec; 51(10):3293-3296. PubMed ID: 31732214
[TBL] [Abstract][Full Text] [Related]
18. Proteasome inhibitor-based primary therapy for antibody-mediated renal allograft rejection.
Walsh RC; Everly JJ; Brailey P; Rike AH; Arend LJ; Mogilishetty G; Govil A; Roy-Chaudhury P; Alloway RR; Woodle ES
Transplantation; 2010 Feb; 89(3):277-84. PubMed ID: 20145517
[TBL] [Abstract][Full Text] [Related]
19. Indicators of treatment responsiveness to rituximab and plasmapheresis in antibody-mediated rejection after kidney transplantation.
Immenschuh S; Zilian E; Dämmrich ME; Schwarz A; Gwinner W; Becker JU; Blume CA
Transplantation; 2015 Jan; 99(1):56-62. PubMed ID: 25121474
[TBL] [Abstract][Full Text] [Related]
20. Long-term outcomes of kidney transplantation across a positive complement-dependent cytotoxicity crossmatch.
Riella LV; Safa K; Yagan J; Lee B; Azzi J; Najafian N; Abdi R; Milford E; Mah H; Gabardi S; Malek S; Tullius SG; Magee C; Chandraker A
Transplantation; 2014 Jun; 97(12):1247-52. PubMed ID: 24854670
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
